Human Immunodeficiency Virus Therapeutics to Advance on back of Biological and Chemical Engineering Technologies

The scourge of human immunodeficiency virus-acquired immunodeficiency syndrome (HIV/AIDS) is spreading fast with thousands of new infections coming to the fore every day. A range of therapeutic regimens target HIV and concomitant infectious pathogens. However, HIV/AIDS management is contingent upon taking long-term medication, with limitations of highly active antiretroviral therapy (HAART) presenting a large gap in the management. Oftentimes, patients have to undergo lifelong medication, leading to the concerns of drug toxicity, high cost of treatment, and high generation rate of escape mutants. These factors aside, the lack of an effective vaccines and low adherence to preexposure prophylaxis (PrEP) have improved the management of HIV.

Get Sample Copy of this Report @

Antibody-mediated Therapy See Considerable Potential

The risk of opportunistic infections is also accelerating the progression of AIDS, causing socioeconomic upheaval in some nations. Meanwhile, for long, researchers have struggled with improving the clinical potential of small-molecule inhibitors, but has faced multiple challenges. More recently, the HIV therapeutics market is seeing a promising therapeutic modality in antibody-mediated therapy. A growing body of research has demonstrated the potential of broad neutralizing antibodies (bnAbs) as anti-HIV therapy, thus broadening the prospects in the HIV therapeutics market. More importantly, a spate of therapeutic antibodies approved by the FDA in recent years is boosting the market. bnAbs hold special potential in the HIV therapeutic market due to its effectiveness to target multiple HIV-1 viral strains.

Strides being made by biological and chemical engineering technologies have helped researchers to test new small-molecule antagonists in randomized phase trials over the past few years. An assortment of antibodies are being tested in clinical trials, thus catalyzing the expansion in the HIV therapeutics market. Anti-HIV bnAbs have been attracting sizable industry findings. On the other hand, strides made in pharmacogenomics and pharmacogenetics will likely open new avenues in the HIV therapeutics market.

Check Table of Contents of this Report @

Positive R&D Scenario to Help HIV Therapeutics Market Gain Traction

San Francisco, California, November 08, 2017: A recent market research report by TMR Research covers the global market for HIV therapeutics. The report, titled “Human Immunodeficiency Virus Therapeutics Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” presents insights into the factors that have the potential of impacting the market, negatively or positively, on a notable level. In addition, valuable inputs and recommendations by industry experts to guide the market players in devising effective growth policies are also included in the report.

The report states the global market for HIV therapeutics is driven by factors such as the rising prevalence of the condition, especially among the young population across the globe, increased attempts by governments aimed at containing the numbers of HIV infected people, and the positive R&D scenario with a constant rise in new patent trials that are conducted every year. Thus the global HIV therapeutics market remains attractive and presents vast scope for any novel drug varieties that can cure the disease. Areas such as pharmacogenomics and pharmacogenetics are witnessing increased attention from companies operating in the HIV therapeutics market. Moreover, a number of new drugs are constantly being developed and clinically tested across the globe. With the easy availability of these new drug varieties, the market for HIV therapeutics is expected to gather pace.

From a geographical standpoint, the manufacturers of HIV drugs in Asia Pacific are facing a tough competitive scenario, coupled with the unique patent laws in several APAC countries, which make it difficult for several branded and effective varieties of HIV therapeutics from reaching the patents. The prices of HIV therapeutics are expected to reduce in the APAC market with the increased participation of several manufacturers in the next few years.

The prevalence of HIV has escalated in Russia, several Caribbean countries, and Latin America. Therefore, the demand for HIV therapeutics in these regions is expected to expand at an encouraging pace in the next few years. The market in Sub-Saharan Africa, which has nearly 70% of the total HIV patient population of the world, is also a key regional market and has a vast pool of unmet demands.

In terms of revenue generation, markets in North America and Europe lead owing to the presence of some of the leading manufacturers of HIV therapeutics across the globe. Other factors such as affordability of novel and costly varieties of HIV drugs, encouraging health insurance policies, and easy availability of novel therapeutics will also continue to bolster these regional markets in the next few years.

The report also presents an in-depth analytical overview of the competitive landscape of the global HIV therapeutics market and profiles some of the leading companies operating in the market. The report emphasizes on company profiles, contact information, inception details, financial overview, business policies and strategies, and recent developments, such as any major mergers and acquisitions. Some of the leading players operating in the global in the global HIV therapeutics market are Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, ViiV Healthcare, F. Hoffmann-La Roche AG, Cipla Limited, Boehringer Ingelheim, AbbVie, Inc., Merck & Co., and Bristol-Myers Squibb Company.

Get Sample Copy of this Report